Ultragenyx Pharmaceutical Inc (RARE) Shares Bought by Bank of America Corp DE

Bank of America Corp DE grew its stake in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 62.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 65,791 shares of the biopharmaceutical company’s stock after purchasing an additional 25,219 shares during the period. Bank of America Corp DE owned approximately 0.13% of Ultragenyx Pharmaceutical worth $5,058,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Swiss National Bank boosted its position in shares of Ultragenyx Pharmaceutical by 5.7% during the 2nd quarter. Swiss National Bank now owns 82,052 shares of the biopharmaceutical company’s stock worth $6,307,000 after purchasing an additional 4,400 shares in the last quarter. Amalgamated Bank boosted its position in shares of Ultragenyx Pharmaceutical by 20.8% during the 2nd quarter. Amalgamated Bank now owns 7,176 shares of the biopharmaceutical company’s stock worth $552,000 after purchasing an additional 1,236 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 52.4% during the 2nd quarter. American Century Companies Inc. now owns 55,975 shares of the biopharmaceutical company’s stock worth $4,303,000 after purchasing an additional 19,255 shares in the last quarter. Strs Ohio boosted its position in shares of Ultragenyx Pharmaceutical by 358.3% during the 2nd quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock worth $422,000 after purchasing an additional 4,300 shares in the last quarter. Finally, Pier 88 Investment Partners LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $446,000. Institutional investors own 96.11% of the company’s stock.

In related news, Director William Aliski sold 19,550 shares of the business’s stock in a transaction dated Monday, October 8th. The shares were sold at an average price of $72.49, for a total value of $1,417,179.50. Following the completion of the transaction, the director now owns 72,610 shares of the company’s stock, valued at approximately $5,263,498.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Shalini Sharp sold 6,700 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $90.07, for a total transaction of $603,469.00. Following the completion of the transaction, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at approximately $5,118,497.96. The disclosure for this sale can be found here. Insiders sold a total of 35,000 shares of company stock valued at $2,700,774 in the last three months. 8.40% of the stock is currently owned by corporate insiders.



RARE has been the subject of several research reports. Canaccord Genuity lifted their price target on Ultragenyx Pharmaceutical from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, August 3rd. Robert W. Baird reaffirmed a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, August 3rd. BidaskClub downgraded Ultragenyx Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 29th. Finally, JMP Securities reaffirmed a “buy” rating and set a $94.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Sunday, September 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $83.83.

Shares of RARE stock opened at $48.62 on Friday. Ultragenyx Pharmaceutical Inc has a twelve month low of $41.67 and a twelve month high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($2.08) by $1.02. Ultragenyx Pharmaceutical had a negative net margin of 703.27% and a negative return on equity of 44.09%. The firm had revenue of $12.79 million during the quarter, compared to the consensus estimate of $5.63 million. During the same quarter in the previous year, the company posted ($1.72) EPS. As a group, equities analysts forecast that Ultragenyx Pharmaceutical Inc will post -4.38 EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Recommended Story: What is the Rule of 72?

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply